Oral gatifloxacin in the outpatient treatment of children with cancer fever and neutropenia

Show simple item record

dc.contributor.author Petrilli, Antonio Sergio
dc.contributor.author Carlesse, Fabianne Altruda
dc.contributor.author Pires Pereira, Carlos Alberto
dc.date.accessioned 2016-01-24T13:49:09Z
dc.date.available 2016-01-24T13:49:09Z
dc.date.issued 2007-10-15
dc.identifier http://dx.doi.org/10.1002/pbc.21124
dc.identifier.citation Pediatric Blood & Cancer. Hoboken: Wiley-liss, v. 49, n. 5, p. 682-686, 2007.
dc.identifier.issn 1545-5009
dc.identifier.uri http://repositorio.unifesp.br/handle/11600/30103
dc.description.abstract Background. Fever in neutropenic (FN) patients requires immediate broad-spectrum antibiotics, however, such patients do not represent a homogeneous population and the majority of them are at low risk of developing complication. Gatifloxacin (GA) is an alternative, though it has not been thoroughly studied in Pediatrics yet. the aim of this study was to evaluate oral CA in oncology pediatric patients with FN and low risk of infectious complications. Methods. We conducted a prospective study in patients submitted to chemotherapy and FN, from the ages of 3 to 21 years old, with solid tumors, acute lymphoid leukemia, and lymphomas without comorbidities and treated as Outpatient with oral GA. Safety and adverse effects were monitored. Results. We evaluated 108 patients with 201 episodes of FN. the average age was 10.8 years, 64.8% of the patients were male. Osteosarcoma accounted for 22% of the episodes, rhabdomyosarcoma for 13%, acute lymphoid leukemia, lymphomas and Ewing sarcoma, for 11% each. Among the 174 episodes exclusively treated as outpatients, the average duration of neutropenia was 4.8 days, the average duration of fever was 2.4 days; the average duration of the treatment was 8.1 days. the treatment was successful in 75.9%, analyzing only the first episodes. No patient died during the study. Adverse events included diarrhea, vomiting, increased liver enzymes, arthralgia, and ECG changes. Conclusion. Oral CA is effective and safe in the management of oncology pediatric patients with FN at low risk of infectious complications in the Outpatient setting. en
dc.format.extent 682-686
dc.language.iso eng
dc.publisher Wiley-Blackwell
dc.relation.ispartof Pediatric Blood & Cancer
dc.rights Acesso restrito
dc.subject febrile neutropenia en
dc.subject gatifloxacin en
dc.subject low risk of infection en
dc.title Oral gatifloxacin in the outpatient treatment of children with cancer fever and neutropenia en
dc.type Artigo
dc.rights.license http://olabout.wiley.com/WileyCDA/Section/id-406071.html
dc.contributor.institution Universidade Federal de São Paulo (UNIFESP)
dc.description.affiliation Universidade Federal de São Paulo, Inst Oncol Pediat, Escola Paulista Med, GRAACC, BR-04023062 São Paulo, Brazil
dc.description.affiliation Univ São Paulo, EPM, Dept Infect Dis, São Paulo, Brazil
dc.description.affiliationUnifesp Universidade Federal de São Paulo, Inst Oncol Pediat, Escola Paulista Med, GRAACC, BR-04023062 São Paulo, Brazil
dc.description.affiliationUnifesp Univ São Paulo, EPM, Dept Infect Dis, São Paulo, Brazil
dc.identifier.doi 10.1002/pbc.21124
dc.description.source Web of Science
dc.identifier.wos WOS:000249085300015



File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search


Browse

Statistics

My Account